A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Osimertinib (Primary) ; SI B001 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sichuan Baili Pharmaceutical
- 27 Jun 2024 Planned End Date changed from 1 Jun 2024 to 1 Aug 2024.
- 27 Jun 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Aug 2024.
- 05 May 2023 Planned number of patients changed from 50 to 14.